(919) 237-4897 info@t3dtherapeutics.com

News + Events

Stay up to date with our latest news

T3D Therapeutics Announces Presentation of Neuroimaging Results From a Phase 2a Trial of T3D-959 in Mild to Moderate Alzheimer’s Subjects at the 20th Annual Meeting of the American Society of Experimental Therapeutics

T3D Therapeutics, Inc. today announced that FDG-PET neuroimaging data from a Phase 2a trial with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in an oral and poster presentation entitled ‘A Neurometabolic Approach to Treating Alzheimer’s...